64Cu-DOTATATE SUVmax in Tumor or Metastases in 128 Patients with NEN
| Parameter | Mean | P |
| Overall | 62.2 (3.3) | — |
| Primary tumor site, grouped | 0.001* | |
| Lung (n = 7) | 63.2 (21.4) | |
| Pancreas (n = 25) | 83.8 (10.1) | |
| Gastrointestinal (n = 73) | 51.5 (2.9) | |
| Unknown primary NEN (n = 23) | 72.3 (7.5) | |
| WHO grade | 0.52 | |
| Grade 1 (n = 31) | 67.4 (7.5) | |
| Grade 2 (n = 84) | 62.0 (3.8) | |
| Grade 3 (n = 6) | 48.7 (22.7) | |
| Overall survival at 24 mo | 0.06 | |
| Alive (n = 99) | 65.6 (3.8) | |
| Deceased (n = 29) | 50.7 (5.7) | |
| PFS at 24 mo | 0.17 | |
| No progression (n = 62) | 66.9 (5.0) | |
| Progression (n = 66) | 57.8 (4.3) |
↵* Post hoc analysis by Tukey identified P < 0.001 for pancreas vs. gastrointestinal SUVmax.
Data in parentheses are SEM.
PFS = progression-free survival.